Table 4.
Assessment of Association between CYP4F2 V433M with Ischemic Stroke and Subtypes of Ischemic Stroke After stratification for Sex
| Population | Subject Groupa | MAF | Pallele | Crude ORs (95% CI) | Adjusted ORs (95% CI) | Pdominant |
|---|---|---|---|---|---|---|
| Men | ||||||
|
| ||||||
| 1 | Control | 0.212 | 1.0 | V/M+M/M vs V/V (ref) | ||
| Ischemic | 0.224 | 0.587 | 1.10(0.81–1.49) | 1.34(0.93–1.92) | 0.112 | |
| LVD | 0.239 | 0.271 | 1.21(0.88–1.61) | 1.56(1.05–2.32) | 0.027 | |
| Lacunar | 0.183 | 0.375 | 0.82(0.51–1.33) | 0.86(0.50–1.48) | 0.578 | |
|
| ||||||
| 2 | Control | 0.242 | 1.0 | V/M+M/M vs V/V (ref) | ||
| Ischemic | 0.269 | 0.243 | 1.36(1.01–1.84) | 1.43(1.06–1.94) | 0.017 | |
| LVD | 0.280 | 0.166 | 1.35(0.95–1.92) | 1.49(1.01–2.20) | 0.042 | |
| Lacunar | 0.274 | 0.257 | 1.37(0.94–2.00) | 1.48(0.98–2.22) | 0.059 | |
|
| ||||||
| 1+2 | Control | 0.227 | 1.0 | V/M+M/M vs V/V (ref) | ||
| Ischemic | 0.258 | 0.141 | 1.26(1.02–1.57) | 1.49(1.16–1.91) | 0.004 | |
| LVD | 0.257 | 0.081 | 1.32(1.04–1.68) | 1.48(1.13–1.93) | 0.004 | |
| Lacunar | 0.242 | 0.715 | 1.16(0.87–1.56) | 1.22(0.89–1.98) | 0.215 | |
|
| ||||||
| Women | ||||||
|
| ||||||
| 1 | Control | 0.230 | 1.0 | V/M+M/M vs V/V (ref) | ||
| Ischemic | 0.267 | 0.226 | 1.28(0.86–1.89) | 1.32(0.80–2.32) | 0.248 | |
| LVD | 0.282 | 0.119 | 1.37(0.89–2.10) | 1.46(0.82–2.62) | 0.198 | |
| Lacunar | 0.227 | 0.220 | 1.06(0.58–1.93) | 1.20(0.54–2.70) | 0.652 | |
|
| ||||||
| 2 | Control | 0.208 | 1.0 | V/M+M/M vs V/V (ref) | ||
| Ischemic | 0.277 | 0.011 | 1.28(0.89–1.84) | 1.32(0.87–2.00) | 0.193 | |
| LVD | 0.274 | 0.050 | 1.37(0.87–2.17) | 1.49(0.87–2.54) | 0.148 | |
| Lacunar | 0.310 | 0.004 | 1.51(0.94–2.43) | 1.68(1.00–2.84) | 0.052 | |
|
| ||||||
| 1+2 | Control | 0.216 | 1.0 | V/M+M/M vs V/V (ref) | ||
| Ischemic | 0.272 | 0.005 | 1.28(0.98–1.67) | 1.29(0.96–1.75) | 0.095 | |
| LVD | 0.268 | 0.023 | 1.24(0.91–1.70) | 1.30(0.89–1.88) | 0.175 | |
| Lacunar | 0.277 | 0.029 | 1.32(0.91–1.91) | 1.41(0.93–2.15) | 0.106 | |
M: major allele; m: minor allele; MAF: minor allele frequency; LVD: large vessel disease.
Pallele: significance of minor allele frequency differences determined by χ2 tests, cases vs. controls; ORs: odds ratios with 95% confidence intervals (CI); Pallele and crude ORs from two case-control populations were combined using Mantel-Haenszel test.
Pdominant: significance of adjusted OR computed with multivariate unconditional logistic regression analysis, adjusting for age, body mass index, hypertension, diabetes, hyperlipidemia and smoking status; Combined adjusted ORs were determined by additional adjustment for different populations.